Article Text

Download PDFPDF

Prognostic Relevance of Celiac Lymph Node Involvement in Ovarian Cancer
  1. Alejandra Martínez, MD*,
  2. Cristophe Pomel, PhD,
  3. Thomas Filleron, PhD,
  4. Marjolein De Cuypere, MD*,
  5. Eliane Mery, MD§,
  6. Denis Querleu, PhD*,
  7. Laurance Gladieff, MD,
  8. Mathieu Poilblanc, MD* and
  9. Gwénaël Ferron, MD*
  1. *Department of Surgical Oncology, Claudius Regaud Comprehensive Cancer Center;
  2. Department of Surgical Oncology, Jean Perrin Comprehensive Cancer Center, Clermont-Ferrand, France; Departments of
  3. Biostatistics,
  4. §Pathology, and
  5. Medical Oncology, Claudius Regaud Comprehensive Cancer Center, Toulouse, France.
  1. Address correspondence and reprint requests to Alejandra Martínez, MD, Department of Surgical Oncology, Claudius Regaud Comprehensive Cancer Center, 20-24, Rue Pont-Saint-Pierre, 31052 Toulouse, France. E-mail: martinez.alejandra{at}claudiusregaud.fr.

Abstract

Objective The aim of the study was to report on the oncologic outcome of the disease spread to celiac lymph nodes (CLNs) in advanced-stage ovarian cancer patients.

Methods All patients who had CLN resection as part of their cytoreductive surgery for epithelial ovarian, fallopian, or primary peritoneal cancer were identified. Patient demographic data with particular emphasis on operative records to detail the extent and distribution of the disease spread, lymphadenectomy procedures, pathologic data, and follow-up data were included.

Results The median follow-up was 26.3 months. The median overall survival values in the group with positive CLNs and in the group with negative CLNs were 26.9 months and 40.04 months, respectively. The median progression-free survival values in the group with metastatic CLNs and in the group with negative CLNs were 8.8 months and 20.24 months, respectively (P = 0.053). Positive CLNs were associated with progression during or within 6 months after the completion of chemotherapy (P = 0.0044). Tumor burden and extensive disease distribution were significantly associated with poor progression-free survival, short-term progression, and overall survival. In multivariate analysis, only the CLN status was independently associated with short-term progression.

Conclusions Disease in the CLN is a marker of disease severity, which is associated to a high-risk group of patients with presumed adverse tumor biology, increased risk of lymph node progression, and worst oncologic outcome.

  • Ovarian cancer
  • Celiac lymph node
  • Cytoreductive surgery
  • Survival

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • The authors declare no conflicts of interest.